GENE SEQUENCING OF EGFR IN HEPATOCELLULAR CARCINOMA PATIENTS
Abstract
Limitations: found no evidence of portal vein invasion but did associate EGFR mutation with hypertension. Larger tumors tend to have more EGFR mutations. Further investigations, such as whole exome sequencing, are required to comprehensively elucidate the genetic modifications in HCC NGS facilitated the identification of numerous distinct gene variants in HCC, encompassing both validated and invalidated mutations. The understanding of the origin and course of hepatocellular carcinoma (HCC) is enhanced by these results, which provide novel perspectives. To completely understand the impact of EGFR genetic change on the development of HCC, it is necessary to have larger patient cohorts.
References
Abou El Azm A. R., Yousef M., Mansour N., Awad A., El Dardiry S. and Abdel Aziz I., (2014). New insights on non-B non-C hepatocellular carcinoma in mid Delta Region, Egypt. Journal of Gastrointestinal Cancer, 45: 276-283.
Berasain C., Ujue Latasa M., Urtasun R., Goñi S., Elizalde M., Garcia- rigoyen O., Azcona M., Prieto J. and Ávila M. A., (2011). Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer. Cancers, 3: 2444-2461.
Brozzetti S., Tancredi M., Bini S., De Lucia C., Antimi J., D’alterio C., De Sanctis G. M., Furlan C., Malpassuti V. C. and Lucatelli P., (2021). HCC in the era of directacting antiviral agents (DAAs): surgical and other curative or palliative strategies in the elderly. Cancers, 13: 3025.
Caruso S., Calderaro J., Letouzé E., Nault J.-C., Couchy G., Boulai A., Luciani A., Zafrani E.-S., Bioulac-Sage P. and Seror O., (2017). Germline and somatic DICER1 mutations in familial and sporadic liver tumors. Journal of Hepatology, 66: 734-742.
Deng L.-L., Gao G., Deng H.-B., Wang F., Wang Z.-H. and Yang Y., (2019). Co-occurring genetic alterations predict distant metastasis and poor efficacy of first-line EGFR-TKIs in EGFR-mutant NSCLC. Journal of Cancer Research and Clinical Oncology, 145: 2613-2624.
Guardiola S., Varese M., Sanchez-Navarro M. and Giralt E., (2019). A third shot at EGFR: new opportunities in cancer therapy. Trends in Pharmacological Sciences, 40: 941-955.
Hassan-Kadle M. A., Osman M. M., Keles E., Eker H. H., Baydili K. N., Ahmed H. M. and Osman A. A., (2022). Clinical characteristics of patients with hepatocellular carcinoma: a single-center 3-year experience from Somalia. International Journal of Hepatology, 2022.
Hsu C.-Y., Lee Y.-H., Huang Y.-H., Hsia C.-Y., Su C.-W., Lin H.-C., Lee R.- C., Chiou Y.-Y., Lee F.-Y. and Huo T.-I., (2013). Ascites in patients with hepatocellular carcinoma: prevalence, associated factors, prognostic impact, and staging strategy. Hepatology international, 7: 188-198.
Ikeda S., Tsigelny I. F., Skjevik Å. A., Kono Y., Mendler M., Kuo A., Sicklick J. K., Heestand G., Banks K. C. and Talasaz A., (2018). Next‐ generation sequencing of circulating tumor DNA reveals frequent alterations in advanced hepatocellular carcinoma. The oncologist, 23: 586-593.
Lee S.-C., Lim S.-G., Soo R., Hsieh W.-S., Guo J.-Y., Putti T., Tao Q., Soong R. and Goh B.-C., (2006). Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma. Pharmacogenetics and Genomics, 16: 73-74.
Li C.-L., Lin Y.-K., Chen H.-A., Huang C.-Y., Huang M.-T. and Chang Y.- J., (2019). Smoking as an independent risk factor for hepatocellular carcinoma due to the α7-nachr modulating the JAK2/STAT3 signaling axis. Journal of clinical medicine, 8: 1391.
Lin C.-H., Yang P.-J., Lin S.-H., Yeh K.- T., Tsao T. C.-Y., Chen Y.-E., Lin S.-H. and Yang S.-F., (2020). Association between EGFR gene mutation and antioxidant gene polymorphism of non-small-cell lung cancer. Diagnostics, 10: 692.
Moustafa E. F. A., Galal G. M., Aly A. and Hemeyda K., (2009). (127) Smoking and the risk of hepatocellular carcinoma among Egyptian patients. A preliminary case-control study. Arab Journal of Gastroenterology, 2: AB54.
Raffetti E., Portolani N., Molfino S., Baiocchi G. L., Limina R. M., Caccamo G., Lamera R., Donato F. and Group B. H. S., (2015). Role of aetiology, diabetes, tobacco smoking and hypertension in hepatocellular carcinoma survival. Digestive and Liver Disease, 47: 950-956.
Ramadan A., El Ebidy G., Elzaafarany M., Galal A., Ibrahem M. and Ali D. M., (2021). Characterization of hepatocellular carcinoma in Mansoura university Hospitals: A case-control study of risk factors. Medical Journal of Viral Hepatitis, 6: 38-45.
Rashed W. M., Kandeil M. A. M., Mahmoud M. O. and Ezzat S., (2020). Hepatocellular Carcinoma (HCC) in Egypt: A comprehensive overview. Journal of the Egyptian National Cancer Institute, 32: 1-11.
Russo F. P., Zanetto A., Pinto E., Battistella S., Penzo B., Burra P. and Farinati F., (2022). Hepatocellular carcinoma in chronic viral hepatitis: where do we stand? International journal of molecular sciences, 23: 500.
Tanaka T., Matsuoka M., Sutani A., Gemma A., Maemondo M., Inoue A., Okinaga S., Nagashima M., Oizumi S. and Uematsu K., (2010). Frequency of and variables associated with the EGFR mutation and its subtypes. International journal of cancer, 126: 651-655.
Zhang J., Chen G., Zhang P., Zhang J., Li X., Gan D. N., Cao X., Han M., Du, H. and Ye Y. A., (2020). The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis. PLoS One, 15: e0228857.
Zhang T. and Junling L., (2016). Driven gene in patients with lung squamous cell carcinoma: analysis of clinicopathologic characteristics and prognosis. Zhongguo Fei Ai Za Zhi, 19.
Zhao S., Wang M., Yang Z., Tan K., Zheng, D., Du X. and Liu L., (2020). Comparison between Child-Pugh score and Albumin-Bilirubin grade in the prognosis of patients with HCC after liver resection using time-dependent ROC. Annals of translational medicine, 8.
Zhou S., Wang H., Jiang W. and Yu Q., (2019). Clinicopathological characteristics and EGFR-TKIs efficacies in lung squamous cell carcinoma patients harboring an EGFR sensitizing mutation. OncoTargets and therapy, 8863- 8871.
Ziada D. H., El Sadany S., Soliman H., Abd-Elsalam S., Salama M., Hawash N., Selim A., Hamisa M. and Elsabagh H. M., (2016). Prevalence of hepatocellular carcinoma in chronic hepatitis C patients in Mid Delta, Egypt: A single center study. Journal of the Egyptian National Cancer Institute, 28: 257-262.
